UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
CELL & GENE THERAPY

Endpoints News

E

Endpoints News

Cell & Gene TherapyBoston, United States
Visit Website

About Endpoints News

The go-to daily news source for the global biopharma industry, Endpoints News covers clinical trials, drug approvals, regulatory decisions, and the business of drug development with a focus that competing outlets rarely match. Founded in 2016 by veteran journalist John Carroll, the publication built its reputation on breaking news and deeply reported stories aimed squarely at the professionals who run, fund, and work inside pharmaceutical and biotechnology companies.

Endpoints reaches a subscriber base of researchers, executives, investors, and regulatory professionals who rely on its coverage to track pipeline developments, FDA and EMA actions, licensing deals, and IPO activity. Its morning newsletter, Endpoints Weekly, and real-time alerts have become standard reading across the industry, distinguishing Endpoints from broader business media through its specialist depth and speed.

The outlet provides coverage across a wide range of therapy areas including oncology, rare disease, gene therapy, immunology, and neuroscience, following assets from early-stage research through approval and commercialisation. In 2022, Endpoints News was acquired by Citeline, a data and intelligence business serving the life sciences sector, which positioned the publication within a broader ecosystem of clinical and commercial intelligence tools.

Based in Boston, Massachusetts, Endpoints operates as a specialist industry media brand with a global editorial remit, covering developments in the United States, Europe, and Asia. Its journalists attend major industry conferences and produce long-form investigative pieces alongside its rapid-fire news output.

Further information is available at endpts.com.

Similar Companies

More in Cell & Gene Therapy

A

Adaptimmune

Adaptimmune is built around a singular conviction: that engineered T-cells can be directed to fight cancer with precision and durability. The clinical-stage biopharmaceutical company focuses exclusively on cancer immunotherapy, developing cell therapies designed to arm a patient's own immune system against malignant disease. The company's pipeline has centred on next-generation T-cell receptor (TCR) therapies. Its named programmes include TECELRA, lete-cel, afami-cel, and uza-cel, all of which have been the subject of significant corporate activity. Adaptimmune announced the sale of these four cell therapies to US WorldMeds, a transaction that marks a strategic inflection point for the organisation and underscores the commercial value of its therapeutic assets. Trading on the Nasdaq under the ticker ADAPY, Adaptimmune has operated as a publicly listed entity, giving investors and industry partners visibility into its governance, pipeline progress and financial position. Its focus on T-cell receptor therapy places it within a specialised and competitive segment of oncology drug development, where target specificity and manufacturing scalability remain defining challenges. As a clinical-stage business, Adaptimmune's work sits at the intersection of translational science and commercial development, with programmes advancing from research through to patient-facing trials. The company publishes its pipeline status and scientific findings openly, providing industry professionals and research partners with access to its methodology and clinical data. Further information is available at adaptimmune.com.

View profile
N

Novartis

Novartis ranks among the world's largest pharmaceutical companies, built on the 1996 merger of Ciba-Geigy and Sandoz, two Swiss chemical and pharmaceutical giants with roots stretching back to the nineteenth century. Headquartered in Basel, Switzerland, the company operates across more than 100 countries and employs hundreds of thousands of people globally, making it one of the defining organisations in modern medicine. Innovative Medicines The core innovative medicines division focuses on developing and commercialising patented treatments across a concentrated set of therapeutic areas. Oncology is a particular strength, with the company having established early leadership in targeted cancer therapies, including kinase inhibitors that reshaped haematology. Cardiovascular, immunology, neuroscience, and ophthalmology round out the primary focus areas. The company's cell and gene therapy ambitions are embodied in platforms that have drawn significant industry attention, positioning Novartis at the frontier of advanced therapeutic modalities. Sandoz & the Generics Legacy For much of its post-merger history, Novartis operated a substantial generics and biosimilars business under the Sandoz brand. In 2023, Sandoz was spun off as an independent publicly traded company, sharpening Novartis's focus entirely on patented innovative medicines. The separation reflected a broader strategic decision to concentrate resources where the company sees its strongest long-term competitive position. Novartis is listed on the SIX Swiss Exchange under the ticker NOVN and on the New York Stock Exchange as NVS, giving it access to deep capital markets to fund its substantial research and development programme. The company consistently ranks among the top spenders on pharmaceutical R&D globally, operating research facilities across Europe, North America, and Asia. Radioligand therapy represents one of the newer strategic bets, combining targeted delivery mechanisms with therapeutic isotopes, an area Novartis has pursued through acquisitions and internal development. The company's commercial pipeline and approved portfolio span small molecules, biologics, and cell-based therapies, reflecting the breadth of its scientific capabilities. Further information is available at novartis.com.

View profile
L

Lonza

Lonza is one of the world's most important enablers of the pharmaceutical and biotechnology industries, providing the manufacturing infrastructure that allows drug developers to bring complex therapies from laboratory discovery to commercial supply. Founded in 1897 and headquartered in Basel, Switzerland, the company has grown from its origins in electrochemical production into a leading contract development and manufacturing organisation (CDMO), listed on the SIX Swiss Exchange under the ticker LONN. Biologics & Cell and Gene Therapy Manufacturing Lonza's core strength lies in biologics manufacturing, where it operates large-scale mammalian cell culture, microbial fermentation, and downstream processing capabilities across facilities in the United States, Europe, and Asia. The company is a principal manufacturing partner for some of the world's best-selling biologics, including monoclonal antibodies and recombinant proteins. Its Ibex Solutions platform offers modular, flexible manufacturing designed to compress timelines and reduce capital requirements for clients developing next-generation therapies. In recent years Lonza has invested substantially in cell and gene therapy manufacturing, establishing dedicated facilities and capabilities for viral vector production, including lentiviral and adeno-associated virus (AAV) vectors, as well as plasmid DNA manufacturing. These services address the rapidly expanding pipeline of advanced therapy medicinal products (ATMPs) requiring specialist GMP production. Small Molecule & Specialty Ingredients Beyond biologics, Lonza has longstanding expertise in small molecule active pharmaceutical ingredient (API) synthesis, including highly potent API handling and peptide manufacturing. Its Capsugel-derived capsule and dosage form business, integrated following the 2017 acquisition, extends its offering into oral drug delivery formats used across multiple therapy areas. With dozens of manufacturing sites globally and a workforce of tens of thousands, Lonza serves clients ranging from emerging biotech companies to major multinational pharmaceutical groups. Its scale, regulatory track record, and breadth of technical capabilities make it a reference partner across oncology, immunology, rare diseases, and infectious disease programmes. Further information is available at lonza.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy